Temozolomide

For research use only. Not for use in humans.

製品コードS1237 別名:CCRG81045, NSC 362856

Temozolomide化学構造

分子量(MW):194.15

Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.

サイズ 価格(税別) 在庫  
10mM (1mL in DMSO) JPY 12600 あり
JPY 13600 あり
JPY 30200 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(68)

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.
特性 Methazolastone is a second-generation alkylating agent.
ターゲット
DNA replication [1]
(L-1210, L-1210/BCNU cells)
体外試験

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NWHifW1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjjOFghcA>? Mlr4TWM2OD1zM{muNlDjiIoEsfMAjVUvQTVizszN NGXFXpYzPTl4MEK4Ni=>
KellyCis83 M3P0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWe0PEBp NUPlfG5DUUN3ME2yOVEvODEkgJpCtgKBkTF3Lke1JO69VQ>? NXjqWFF5OjV7NkCyPFI>
SK-N-AS M2HufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVe0PEBp NIHPU3NKSzVyPUKyO{44OOLCidMx5qCKOjJwMUWg{txO MoK4NlU6PjB{OEK=
SK-N-ASCis24 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf2bYk1QCCq MWfJR|UxRTR6MD62NQKBkcLz4pEJNVAyNjF3IN88US=> NUTadmxXOjV7NkCyPFI>
CHP-212 MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jIOlQ5KGh? NUD6S5Y3UUN3ME23Mlk46oDLwsJihKkxNjZ7IN88US=> NHfIbmEzPTl4MEK4Ni=>
CHP-212Cis100 NGjCPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm0PEBp MXvJR|UxRTlwNUZihKnDueLCiUCuPFgh|ryP M{jCZVI2QTZyMkiy
U87  NUHDeos4TnWwY4Tpc44hSXO|YYm= NV\YOm1GOTByIN88US=> Mm\SNlQuPzJiaB?= MmrSbY5lfWOnczDEZ3IyKGW6cILld5Nqd25? NVjYWWFEOjV6MEi4Olg>
LN229 NIr5PVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHmNE02OCEQvF2= Mlm0TWM2OD1zNjFOwG0> M1vlVFI2PzVyMkez
TR-LN229 NVi3VFRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[0NE02OCEQvF2= NYO0dnpmUUN3ME23O{DPxE1? NVn6WGRJOjV5NUCyO|M>
U87  M{PLO2Fxd3C2b4Ppd{BCe3OjeR?= NWWxepJ2OOLCk{KwNQKBkcL3TR?= MVKyOEBp NGXXc21mdmijbnPld{BEWSCrbnT1Z4VlKGGyb4D0c5Nqew>? M3jaclI2PjhzNk[4
U251MG NHrqWZhCeG:ydH;zbZMhSXO|YYm= NUHrPZVvOTBywrFOwG0> NUL4dZBFPDhiaB?= NEDBTHVRSlN? NVz3ZW0zcW6mdXPld{BieG:ydH;zbZM> NF7he|EzPTZ6MES2OC=>
U87MG MYrBdI9xfG:|aYOgRZN{[Xl? MUWxNFDDqM7:TR?= Ml24OFghcA>? M3XQbXBDWw>? M3TxXYlv\HWlZYOgZZBweHSxc3nz NEDLVZozPTZ6MES2OC=>
U87 NXjRV3BnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUGxUmtXPTBvM{WwJO69VQ>? NFXPRnc1QMLiaNMg M1:1NolvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 MnTLNlU2PTR{MkO=
U118  MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUC3dllyPTBvM{WwJO69VQ>? NWjScIQ1PDkEoHlCpC=> NWrqZ5I4cW6qaXLpeJMh[2WubDDndo94fGhic3zp[4h1dHl? M4HhS|I2PTV2MkKz
U87 M4rITGZ2dmO2aX;uJGF{e2G7 NFrzVG4zPTBxM{WwJO69VQ>? MlP2OFjDqGkEoB?= M3LCToVvcGGwY3XzJHROYC2rbnT1Z4VlKHBvUFvDMZBidiCmZXPy[YF{\Q>? NYnWdGh[OjV3NUSyNlM>
U118  NGrlSFJHfW6ldHnvckBCe3OjeR?= NUXnWlc2OjVyL{O1NEDPxE1? NWTGZ|BbPDkEoHlCpC=> NHLM[5hmdmijbnPld{BVVVhvaX7keYNm\CCyLWDLR{1x[W5iZHXjdoVie2V? NGP0TFYzPTV3NEKyNy=>
U87 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHhNlUxNzN3MDFOwG0> M1n5OFQ5yqCqwrC= NFLORYxqdmO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubIOgbY4hWyCjbnSgS|IwVcLiY3;0doVifGWmIIfpeIghXE2[ MYmyOVU2PDJ{Mx?=
A375 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XscVQ5yqCqwrC= NWm1S3BwUUN3ME2yOlUh|ryP M2qxNFI2PTJ2NUWy
A2058 NHnsVY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X1VlQ5yqCqwrC= MVrJR|UxRTF{IN88US=> NEOzXWQzPTV{NEW1Ni=>
M238 MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\ZOFjDqGkEoB?= NIj1OZpKSzVyPUSwJO69VQ>? Mn24NlU2OjR3NUK=
M249 NH[1RpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDRdmc3PDkEoHlCpC=> MYDJR|UxRTJ3NDFOwG0> MXqyOVUzPDV3Mh?=
M21 NGq3R45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUC0POKhcMLi MoTMTWM2OD1{MkGg{txO NV7oSYJCOjV3MkS1OVI>
U251 NXywd4J7S3m2b4TvfIl1gSCDc4PhfS=> MV:yNEDPxE4EoB?= MnXsOFjDqGkEoB?= M2fKW5Jm\HWlZXTzJJRp\SCyZYLj[Y51[WenczDv[kBkd2yxbnnld{Bnd3KvZXS= Mlm3NlU1OzR|OEG=
LN229 MWDDfZRwfG:6aYT5JGF{e2G7 MWKyNEDPxE4EoB?= MWm0POKhcMLi M2Xx[5Jm\HWlZXTzJJRp\SCyZYLj[Y51[WenczDv[kBkd2yxbnnld{Bnd3KvZXS= NGfaWVIzPTR|NEO4NS=>
U373MG-LUC MnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vZTVczKGh? MnX6TWM2OD54MECg{txO NFnIfFQzPTR|MUm1Ny=>
U87  MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf1NlUuOjByIN88US=> MVO0POKhcMLi MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{LYeFI2PDByN{S1
U251 Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;1Nnc6OjVvMkCwJO69VQ>? M3;zc|Q5yqCqwrC= MlrxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MknxNlU1ODB5NEW=
U251 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv2PY4yODBvNECwJO69VQ>? M3;yeVczNzl4IHi= MlPDeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi NGmxUpozPTN5NUK3NS=>
U373 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXflXVRROTByLUSwNEDPxE1? Ml7rO|IwQTZiaB?= NGf3S2l1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= NHzlW2czPTN5NUK3NS=>
U343 M3vv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLiNVAxNTRyMDFOwG0> MkjPO|IwQTZiaB?= Mne5eIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi M3PVelI2Ozd3Mkex
U87MG-luc2 NGXBWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K2XFExOC12MECg{txO M3XoS|czNzl4IHi= MnPKeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi MYmyOVM4PTJ5MR?=
U87 NYTwSY9uTnWwY4Tpc44hSXO|YYm= NYOz[YM3OjByIN88US=> Mn3IOFghcA>? NEnGblhqdmO{ZXHz[ZMhSlKFQ{OgcXJPSSCneIDy[ZN{cW:w MWOyOVM{Pzd{MR?=
U251 MkC3SpVv[3Srb36gRZN{[Xl? MYiyNFAh|ryP M2LPVVQ5KGh? NH\mNmZqdmO{ZXHz[ZMhSlKFQ{OgcXJPSSCneIDy[ZN{cW:w M2rJcFI2OzN5N{Kx
A172 NGDZc4hHfW6ldHnvckBCe3OjeR?= NYXkVXhVOjByIN88US=> NX;lNZhEPDhiaB?= NV7Fe|FWcW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= NXnzOXNVOjV|M{e3NlE>
U251 MXfGeY5kfGmxbjDBd5NigQ>? MX6yNFAh|ryP MVu0PEBp MoLabY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? MX6yOVM{Pzd{MR?=
A172 NEDHbGVHfW6ldHnvckBCe3OjeR?= NFrUbIkzODBizszN NHPVd3g1QCCq NWLkWXlFcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEKUQ1GxMEBDWkODMjygVmFFPTFiYX7kJGZCVkOGMh?= Mnf3NlU{Ozd5MkG=
U87 M4TZZWZ2dmO2aX;uJGF{e2G7 NUCzPYltOjByIN88US=> M3nISVI1Nzd{L{GyNEBp NVzTXnBCcW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 MVSyOVM{Pzd{MR?=
U251 MmrGSpVv[3Srb36gRZN{[Xl? M{DOWlIxOCEQvF2= MoLZNlQwPzJxMUKwJIg> MY\pcoNz\WG|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk> NV;4ZpZqOjV|M{e3NlE>
A172 MoH5SpVv[3Srb36gRZN{[Xl? MU[yNFAh|ryP NFzaNVEzPC95Mj:xNlAhcA>? M1;qc4lv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? MlHnNlU{Ozd5MkG=
SNB19V MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWG3JIQ> Mm[2SG1UVw>? NWrjWpU{T0l3ME2zOU44yrFzMjFOwG0> NWW3[|hWOjV{N{e0OFE>
SNB19M MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[5O{Bl MnXNSG1UVw>? MXXHTVUxRTR4OT65xtE5QCEQvF2= NID0c3czPTJ5N{S0NS=>
SNB19VR NEPHVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVe3JIQ> M{fYcWROW09? NI\IdVRIUTVyPUK4NE4zyrFzODFOwG0> M{DjeFI2Ojd5NESx
U373V NGrGepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjMTpAyPyCm M4HuV2ROW09? NEj4OXpIUTVyPU[4MlDDuTN{IN88US=> MUmyOVI4PzR2MR?=
U373M NXXaPFN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzJO{Bl MUDEUXNQ NWnMd3Y6T0l3ME2zOlgvP8LzOE[g{txO NInIcG4zPTJ5N{S0NS=>
U373VR Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXe3JIQ> M{XibmROW09? NV;pPIdWT0l3ME2yPFgvQMLzM{Og{txO M2PGSFI2Ojd5NESx
U87MG MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jKZlch\A>? NYHIbIdNTE2VTx?= NYDT[IZNT0l3ME2zPE4{yrF{MDFOwG0> NUj3XXg4OjV{N{e0OFE>
HCT116 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DaVlch\A>? M171W2ROW09? M1frfmdKPTB;NUe5MlnDuTN{IN88US=> MW[yOVI4PzR2MR?=
DLD1 MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH5O{Bl NYCwXZV6TE2VTx?= NInj[4xIUTVyPUWwNU41yrF7MzFOwG0> NXzQRWtkOjV{N{e0OFE>
MRC5 M2\hdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYK3JIQ> MWLEUXNQ MWHHTVUxRTR2OT60xtE5KM7:TR?= M2Sx[VI2Ojd5NESx
SNB19V  M4[zVGZ2dmO2aX;uJGF{e2G7 M2jiOlExOCEQvF5CpHROYg>? NV:3b5lxOC15MjDo NEDzNnBqdmO{ZXHz[ZMh|rOKMlHYJIV5eHKnc4Ppc44h[mW2d3XlckAyPiCjbnSgO|IhcA>? M2HETFI2Ojd5NESx
T98G  NV7vfYJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[1M|ExNzF3IN88US=> NEK0ZnczPMLiaB?= NV25TnBXcW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wt[IVx\W6mZX70cJkh[W[2ZYKgZ49v[2:vaYThcpQufGWvb4rvcI9ucWSnIIfpeIghVlCnNj3QSHQ> MYKyOVI3Ojl4MR?=
U251  MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX4Umg2NzFyL{G1JO69VQ>? NWTKfJE4OjUEoHi= NHnpe2FqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=> NYLjfmRMOjV{NkK5OlE>
T98G  MVLGeY5kfGmxbjDBd5NigQ>? M3PrW|E2KM7:TR?= M1PnVlI1yqCq M4T5dolv[3KnYYPld{BFVkFvZoLh[41mdnSjdHnvckBqdiCQUHW2MXBFXCC2cnXheIVlKGeuaX;tZUBk\Wyucx?= M4mxbVI2OjZ{OU[x
U251  NIS3XnBHfW6ldHnvckBCe3OjeR?= M3zFNFE2KM7:TR?= MXeyOOKhcA>? M2jpSolv[3KnYYPld{BFVkFvZoLh[41mdnSjdHnvckBqdiCQUHW2MXBFXCC2cnXheIVlKGeuaX;tZUBk\Wyucx?= MmS2NlUzPjJ7NkG=
U-87 MG NVHESZc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDwTYw4OiCq NH[3VHpKSzVyPUCuPVMhdU4EoB?= Mnm3NlUzPDV|M{K=
U-118 MG NWLpT4h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[0[YI4OiCq M{eweWlEPTB;MT6wOUBuVcLi NYOzbGJZOjV{NEWzN|I>
U87 NUHQ[3M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfvVIkzPCCq MkDzTWM2OD1{NkCuN|Qh|ryPwrC= MmP2NlUyPzN{M{O=
U87 GSLCs MmXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm4NlQhcA>? NY\DRpRGUUN3ME23OlYvOTFizszNxsA> M{m2WFI2OTd|MkOz
U87MG NGHTe|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYS3NkBp MUDJR|UxRTF3Lk[yOUDPxE4EoB?= MnvONlUxPTB7MUW=
U251 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17seFExOC12MECg{txO NHL0e5Y1QCCq NFLWV2dFVVOR M4fhb4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NH[yT5UzPDZ{M{ezOi=>
U87 NHrmR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1e5RlExOC12MECg{txO NYfmNHY6PDhiaB?= MVLEUXNQ NGPGdnZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3jpdFI1PjJ|N{O2
MDA-MB-231-br MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWqwMVExKM7:TR?= MUW0PEBp MmHHSG1UVw>? NWLMeJFucW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2DQNlI1PjJ|N{O2
HCC-1937 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfBZmIxNTNyMDFOwG0> M1;jNFQ5KGh? NIP2NFFFVVOR NVX2fJpCcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWjOTXJ2OjR4MkO3N|Y>
MDA-MB-231 M3zHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDJNE01OCEQvF2= NGmzeZY1QCCq MXvEUXNQ NY\vOI9rcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnXqNlQ3OjN5M{[=
MDA-MB-468 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\EV5UxNTVyMDFOwG0> M1:wd|Q5KGh? NXLYWWV3TE2VTx?= NHnvNFZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MofFNlQ3OjN5M{[=
T47D M{\uemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KxfFAuOTByIN88US=> M{nNdlQ5KGh? NHq3UXpFVVOR NHqySZNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mn;RNlQ3OjN5M{[=
MCF7 MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LRNVAuOTByMDFOwG0> M2rvflQ5KGh? M1vNWmROW09? NInacJFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlPsNlQ3OjN5M{[=
Hs683 NHPVe|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\TSmQxNTFyMECg{txO Ml7jPVYhcA>? M2j0NWlEPTB;MUK4Mlkh|ryP MlXTNlQ1QTV7MEe=
U87 NFvwcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWCyeY1kOC1zMECwJO69VQ>? NVvQOXIyQTZiaB?= NWfOU3YyUUN3ME2xPE41PSEQvF2= NUXwRXlxOjR2OUW5NFc>
LNZ308 M1HTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVywMVExODBizszN MVO5OkBp MXLJR|UxRTN{Nj63JO69VQ>? NEjJOFkzPDR7NUmwOy=>
U87 NXyySlNLSXCxcITvd4l{KEG|c3H5 NV65eJlVOTByIN88US=> NVLDc3BlPDhiaB?= NXLmVZBTTE2VTx?= NV:wWYxFcW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=> MWSyOFQ5OTV6Nh?=
U251  M4XSZWFxd3C2b4Ppd{BCe3OjeR?= NUi2VWU6OTByIN88US=> MWq0PEBp MnHDSG1UVw>? NYXsPI4{cW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=> M1nrcFI1PDhzNUi2
U251 NVfXdIU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPt[WozPCCq NWfabnd4UUN3ME24Ok4zQeLCidMx5qCKOS53ODFOwG0> NVvCcFV[OjR|Mk[5OVQ>
U251 M{PVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvMVpl2PDhiaB?= NEDWW2hKSzVyPUe1MlM16oDLwsJihKkyNjB{IN88US=> MnzVNlQ{OjZ7NUS=
U251 NHXuZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3npbFczKGh? MkTqTWM2OD15Mj60NwKBkcLz4pEJNU41PSEQvF2= NULO[3pWOjR|Mk[5OVQ>
U251 M2XmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO3NVRCQTZiaB?= MWDJR|UxRTZ7Lkiy5qCKyrIkgJmzMlA1KM7:TR?= NIjhPWwzPDN{Nkm1OC=>
T98G NX;renBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33iflAuPzVyIN88US=> MV23Nk86PiCq MonZbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MVqyOFMzPDB6MB?=
U251-MG MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXKRlkxNThyMDFOwG0> NVS5UXNVPzJiaB?= NFvMdWNqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M{TT[FI1ODl|NkOw
D54-MG NWPWXZF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjsXZlWOC16MECg{txO Ml3xO|IhcA>? MknTbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MUWyOFA6OzZ|MB?=
SHG-44 MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHzeZAyOC1{MECg{txO MXi5OkBp NIrxVHdKSzVyPUmuO|MhyrFiMj6xNkDPxE1? Mn2zNlQxPjV3Nkm=
U373  NWHqfWVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrHTXAyOC1{MECg{txO M{ThN|k3KGh? M2e5R2lEPTB;MUCuNVMhyrFiMT6wNkDPxE1? NYj1c|Q5OjRyNkW1Olk>
HT-29  MWrGeY5kfGmxbjDBd5NigQ>? NXjPVlBzPTByIN88US=> M4D6blI1NzR6IHi= NX;2SFVH\W6qYX7j[ZMhfGinIHzleoVteyCxZjFOt{1JOkG[wrC= MVWyOFA{QDB4OB?=
PC-3  M17sbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmWxNE0zPSEQvF2= NVjvSY1mPDhiaB?= MXvpcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mVicH;0[Y51cWG2ZXSgZpkhdHmlb4DlcoU> M4[ySlI{PzR4OUO0
PC-3  MYrBdI9xfG:|aYOgRZN{[Xl? MVeyOUDPxE1? NGLWZ2k1QCCq NGPROWtqdmS3Y3XzJIFxd3C2b4Ppd{B4cGmlaDDjZY4h[mVicH;0[Y51cWG2ZXSgZpkhdHmlb4DlcoU> NX3WbItUOjN5NE[5N|Q>
T98G NXHQN2ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTNOVAuPDByIN88US=> MlXMNVQ1KGh? NX7VVnhCcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M3XYXlI{PzF3NEm5
U87-MG M{D1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljGNVAxKML3TR?= NXuzZY9PPzJiaB?= NHu4[|FqdmirYnn0d{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkhT1SE NXS3OIdxOjN4OU[3PFg>
U251-MG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvae4hOOTByINM1US=> M3K0TVczKGh? MWfpcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mViZX7oZY5k\WRiYomgS3RD Mmn1NlM3QTZ5OEi=
LNT-229 MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUWzMVExOCEQvF2= M2WzWlI1KGh? MUTpcohq[mm2czDjcI9vd2enbnnjJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NHfISGUzOzZ4N{[zNi=>
T98G M17X[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD3dopyOTBvN{CwJO69VQ>? MljKNlQhcA>? Mnn0bY5pcWKrdIOgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NF7TUpUzOzZ4N{[zNi=>
U87  NHzDXHhHfW6ldHnvckBCe3OjeR?= NYLGdWpEOTByINM1US=> NH7seY4{KGh? MoG2[YxmfmG2ZYOgeIhmKGyndnXsd{Bw\iCyQ3jrNUBidmRicFPob|I> Mmf1NlM3Pjd2Nkm=
HCT116 MXzGeY5kfGmxbjDBd5NigQ>? MnjqNVAxKML3TR?= MXWzJIg> NHLPd4JqdmS3Y3XzJJRp\SCFaHuxJHBpd3OyaH;yfYxifGmxbh?= NEfZPHIzOzZ4N{S2PS=>
HCT3-6 NHXBW2xHfW6ldHnvckBCe3OjeR?= NGHKNGwyODBiwsXN NFH5[VA{KGh? NUXsZ2p[cW6mdXPld{B1cGViQ3jrNUBRcG:|cHjvdplt[XSrb36= NF7sPZUzOzZ4N{S2PS=>
U-87  MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj6bmsxNTRyIN88US=> MX2xNkBl MX\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NIHEU3AzOzZ2NUeyPS=>
U-87  MmPnRZBweHSxc3nzJGF{e2G7 MViwMVQxKM7:TR?= MnPBN{83KGR? NGDST5BqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NV\SXFdLOjN4NEW3Nlk>
U-87  M3q4fWZ2dmO2aX;uJGF{e2G7 M3\ZfVAuPDBizszN MVuzM|Yh\A>? MmOwbY5lfWOnczDheZRweGijZ4mgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NVi4NlZEOjN4NEW3Nlk>
GB-SCC010 NFvxPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTnZ|EzPCCm M174[GlEPTB;MkK2JO69VQ>? MoHxNlM3OTJ5NUW=
GB-SCC026 NGfjemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTGboI2PCCm MXrJR|UxRTV|LkGg{txO M{nGNFI{PjF{N{W1
GB-SCC028 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3QOEBl NWXjeVNwUUN3ME2xOlch|ryP M{[5XFI{PjF{N{W1
U87 M1;UU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PmV|Qh\A>? MkO1TWM2OD12NT6yJO69VQ>? NVixVopUOjN4MUK3OVU>
U87 stem cell MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIKzUYg1KGR? NWOyW|M2UUN3ME22Ok44KM7:TR?= M4XK[FI{PjF{N{W1

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
pERK / ERK / p-p38 / p38; 

PubMed: 24436439     


Cells were treated with TMZ (0.5 mM) time dependently, and Western blotting was used to analyze for phosphorylated ERK and p38 MAPK expression.

DR5 / c-FLIP / Survivin / XIAP; 

PubMed: 24436439     


Western blot analysis showing expressions in DR5 and antiapoptotic proteins (c-FLIP, survivin, and XIAP) in glioma cells treated with increasing doses of TMZ (0–2 mM) for 24 hours. 

24436439
Growth inhibition assay
Cell viability; 

PubMed: 25751281     


Distinct temozolomide-resistance for MGMT-expressing (SF767) and MGMT-negative (U87) GBM cells was assessed.

25751281
Immunofluorescence
Phalloidin / Phospho-H2A.X; 

PubMed: 27375225     


Immunofluorescence analysis of the level of phospho-H2A.X in nucleus which can reflect DNA damage response increased significantly at day 6, peaked during days 7-10 and decreased significantly at day 12 after treatment temozolomide (200 μM). 

cleaved caspase-3; 

PubMed: 25663820     


Representative Photomicrographs of cleaved caspase-3 immunoreactivity in control (DMSO treated) and treated group of U87 cells. Base line immunofluorescence was detected in control group. Significant Increase in immunofluorescence is detected in all treated groups with the highest observed intensity in combination treatment group (NA-2 + TMZ).

27375225 25663820
体内試験 After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

- 合併
  • 細胞株: L-1210 and L-1210/BCNU cells
  • 濃度: 0 μM -100 μM
  • 反応時間: l hours
  • 実験の流れ:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (参考用のみ)
動物試験:

[1]

- 合併
  • 動物モデル: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • 投薬量: 40 mg/kg
  • 投与方法: Administered via i.v.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
2mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 194.15
化学式

C6H6N6O2

CAS No. 85622-93-1
保管
in solvent
別名 CCRG81045, NSC 362856
Smiles CN1N=NC2=C(N=C[N]2C1=O)C(N)=O

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(余分な消耗を考慮し動物一匹分の量を用意することをお勧めします。)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロットごとに組成が異なるため、セレックから完全に溶解できる組成をお求めください。)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04238819 Not yet recruiting Drug: Abemaciclib|Drug: Irinotecan|Drug: Temozolomide Relapsed Solid Tumor|Refractory Solid Tumor Eli Lilly and Company July 31 2020 Phase 1
NCT04388475 Not yet recruiting Drug: OKN-007|Drug: Temozolomide (TMZ) Recurrent Malignant Glioma|Brain Glioblastoma Oblato Inc. May 25 2020 Phase 2
NCT03796507 Not yet recruiting Drug: Temozolomide Glioma of Brain University of Rochester|National Institutes of Health (NIH) March 1 2020 Early Phase 1
NCT04200066 Not yet recruiting Drug: Temozolomide Tamoxifen Maprotiline Glioblastoma|Brain Tumor University of Rochester February 1 2020 Phase 1
NCT04091503 Not yet recruiting Drug: Intranasal Modified Temozolomide Glioma Malignant|Gliosarcoma|Astrocytoma of Brain Center Trials & Treatment Europe December 10 2019 Phase 1
NCT03932981 Recruiting Drug: Temozolomide Adult Brainstem Glioma Assistance Publique - Hôpitaux de Paris July 26 2019 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

Tags: Temozolomideを買う | Temozolomide ic50 | Temozolomide供給者 | Temozolomideを購入する | Temozolomide費用 | Temozolomide生産者 | オーダーTemozolomide | Temozolomide化学構造 | Temozolomide分子量 | Temozolomide代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID